Value of Life Sciences Innovation
Featured Topics
Lead story
Other featured articles
-
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Posted in -
Targeted Therapies Linked to Improved Outcomes for Advanced-Stage Breast Cancer Patients
Targeted therapies accounted for about 90% of new active substance approvals in oncology between 2011 and 2018.
Posted in -
Don’t Make Surgery Another COVID Casualty
Investing in minimally invasive tools can free up valuable beds when pandemic surges threaten to overwhelm hospitals, argues Van Nuys and Lakdawalla in MedPage Today.
Posted in -
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
This Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Posted in
Our Work In Value of Life Sciences Innovation
-
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
Categorized in -
Health Technology Assessment in the U.S. – A Vision for the Future
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.
Categorized in -
Paying for Cell and Gene Therapies in Medicare
Join Schaeffer Center Director Dana Goldman in conversation with Jeet Guram and Kathy Buto about policy lessons learned and potential solutions to support innovation and patient access in cell and gene therapies.
Categorized in -
Making Progress in Cancer Diagnostics: Clinical Practice and Policy
Join the Health, Medicine and Society Program of the Aspen Institute and the USC Schaeffer Center for a webinar on new clinical advances in cancer screening and the policy issues surrounding access to and adoption of these advances.
Categorized in -
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Categorized in -
Yes, We Need a Vaccine to Control COVID-19. But We Need New Treatments, Too.
New treatments for Covid-19 are needed before a vaccine is ready and as the essential backstop to manage it afterward, since vaccines aren’t perfect.
Categorized in